Capstan Therapeutics
Michael Rosenzweig is Capstan’s EVP of Portfolio Strategy and Product Development. He most recently served as an Entrepreneur in Residence at RA Ventures. He has more than two decades of experience in pharma and biotech including leading Oncology and Immunology Discovery at Merck Research Labs as well as in leadership roles at Immunext and ToleRx. He is a member of the Board of Directors of Bright Peak and the Scientific Advisory Board of Avilar.
This person is not in any offices
Capstan Therapeutics
2 followers
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.